21.7 C
Munich
Sunday, June 30, 2024
- Advertisement -
- Advertisement -spot_img

TAG

PROTOFIBRIL

EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER’S DISEASE IN JAPAN

TOKYO and CAMBRIDGE, Mass., Jan. 15, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB,...

Latest news

- Advertisement -spot_img